Enlivex Therapeutics Files 6-K with Financials
Ticker: ENLV · Form: 6-K · Filed: Aug 30, 2024 · CIK: 1596812
Sentiment: neutral
Topics: financials, 6-K, foreign-private-issuer
Related Tickers: ENLV
TL;DR
Enlivex (ENLV) dropped its Q2 2024 financials via 6-K, check it for cash burn and runway.
AI Summary
Enlivex Therapeutics Ltd. filed a Form 6-K on August 30, 2024, reporting its unaudited condensed consolidated financial statements for the period ending June 30, 2024. The company, formerly known as Bioblast Pharma Ltd., is based in Tel Aviv, Israel, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides investors with an update on Enlivex Therapeutics' financial position as of mid-2024, crucial for assessing the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Enlivex Therapeutics faces inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Filer of the report
- Bioblast Pharma Ltd. (company) — Former name of Enlivex Therapeutics Ltd.
- August 30, 2024 (date) — Filing date of the 6-K
- June 30, 2024 (date) — End of the reporting period for financial statements
FAQ
What is the filing date of this Form 6-K?
This Form 6-K was filed on August 30, 2024.
What period do the financial statements in this filing cover?
The unaudited condensed consolidated financial statements cover the period ending June 30, 2024.
What is the principal executive office address of Enlivex Therapeutics Ltd.?
The principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel 7403618.
Has Enlivex Therapeutics Ltd. changed its name previously?
Yes, the company was formerly known as Bioblast Pharma Ltd., with a name change on September 19, 2016, and prior to that, BIO BLAST PHARMA LTD. with a name change on January 13, 2014.
Under which form will Enlivex Therapeutics Ltd. file its annual reports?
Enlivex Therapeutics Ltd. files its annual reports under cover of Form 20-F.
Filing Stats: 361 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2024-08-30 16:30:38
Filing Documents
- ea0212098-6k_enlivex.htm (6-K) — 17KB
- ea021209801ex99-1_enlivex.htm (EX-99.1) — 529KB
- ea021209801ex99-2_enlivex.htm (EX-99.2) — 93KB
- 0001213900-24-074559.txt ( ) — 4392KB
- enth-20240630.xsd (EX-101.SCH) — 53KB
- enth-20240630_cal.xml (EX-101.CAL) — 39KB
- enth-20240630_def.xml (EX-101.DEF) — 210KB
- enth-20240630_lab.xml (EX-101.LAB) — 416KB
- enth-20240630_pre.xml (EX-101.PRE) — 224KB
- ea0212098-6k_enlivex_htm.xml (XML) — 610KB
Financial Statements
Financial Statements The unaudited condensed consolidated financial statements for Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (" Enlivex "), as of and for the three and six month periods ended June 30, 2024 and 2023 , and the Operating and Financial Review and Prospects of Enlivex for the corresponding periods are furnished as Exhibits 99.1 and Exhibit 99.2, respectively, to this Report on Form 6-K and incorporated by reference into Enlivex's registration statements on Forms S-8, F-3 and F-3MEF (File No. 333-256799 , File No. 333-232413 , File No. 333-232009 , File No. 333-252926 and File No. 333-264561 ) , filed with the Securities and Exchange Commission. Exhibit No. 99.1 Unaudited condensed consolidated financial statements for Enlivex as of June 30, 2024 and December 31, 2023 and for the three and six month periods ended June 30, 2024 and 2023. 99.2 Operating and Financial Review and Prospects as of and for the three and six month periods ended June 30, 2024 and 2023. 101.INS Inline XBRL Instance Document 101.SCH Inline Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Defeinition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Oren Hershkovitz Title: Chief Executive Officer Date: August 30, 2024 2